在早期三阴性乳腺癌中接受新辅助化疗加杜尔瓦卢马布后的周围血液免疫参数,反应和不良事件

Julia Foldi1,2,3, Kim R M Blenman4,5,6, Michal Marczyk4,7

  • 1Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, CT, USA. Foldij@upmc.edu.

概括

在接受化疗加杜瓦卢马布的三阴性乳腺癌 (TNBC) 患者的免疫细胞受体多样性和细胞因子水平没有预测治疗反应. 然而,基线细胞因子可以预测与免疫相关的不良事件 (irAEs).

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...